Ideagen (LON:IDEA) has been reiterated to Corporate in a statement by finnCap earlier today.
- Updated: October 15, 2016
finnCap has reiterated Ideagen (LON:IDEA) to Corporate in a statement released on 10/13/2016.
On 9/06/2016, finnCap released a statement about Ideagen (LON:IDEA) maintained the target price at 69.00GBX that suggested an upside of 0.2%.
Having a price of 57.50GBX, Ideagen (LON:IDEA) traded 0.00% even on the day. With the last stock price up 2.19% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. IDEA has recorded a 50-day average of 55.40GBX and a two hundred day average of 53.82GBX. Trade Volume was down over the average, with 48,060 shares of IDEA changing hands under the typical 128,832
Recent Performance Chart
With a total market value of 0 GBX, Ideagen has price-earnings ratio of 78.57 with a one year low of 44.11GBX and a one year high of 60.00GBX .
Brief Synopsis About Ideagen (LON:IDEA)
Ideagen plc is a provider of enterprise governance, risk, and compliance (eGRC) and healthcare information management software for organizations operating within regulated industries. The Company offers GRC solutions, which offers products, such as Pentana, Q-Pulse, Quality Workbench, Proquis Enterprise, KnowledgeWorker and Ideagen Capture. It offers GRC solutions for industries, such as accounting and finance, aerospace and defense, automotive, and others. The Company offers healthcare solutions, which offers products, such as dartCAPTURE, darted, dartEMR, dartKW, dartOCM, dartQSCAN, PatientFirst and Q-Pulse. It offers healthcare solutions for departments, such as medical record archiving, pathology (laboratory), radiology and others. The Company offers content solution, such as Easysite, which manages sites online, inline and in real time. It offers Easysite for content management, digital asset management, site management, social and personalization, Context Management and others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.